NxStage Medical (NASDAQ:NXTM) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Market Beat reports.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

Separately, TheStreet cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, July 8th.

In other news, SVP Winifred L. Swan sold 2,500 shares of NxStage Medical stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $14.71, for a total value of $36,775.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joseph E. Turk, Jr. sold 2,000 shares of NxStage Medical stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $13.86, for a total value of $27,720.00. The disclosure for this sale can be found here.

NxStage Medical (NASDAQ:NXTM) traded down 0.21% during midday trading on Thursday, hitting $13.99. The company had a trading volume of 441,493 shares. The company’s 50 day moving average is $14.65 and its 200-day moving average is $16.84. NxStage Medical has a one year low of $13.83 and a one year high of $14.18. The company’s market cap is $884.70 million.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Wednesday, May 6th. The medical device company reported ($0.09) EPS for the quarter, topping the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $79.50 million for the quarter, compared to analyst estimates of $77.92 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. NxStage Medical’s revenue was up 10.1% compared to the same quarter last year. On average, equities analysts predict that NxStage Medical will post ($0.36) EPS for the current year.

NxStage Medical, Inc. (NASDAQ:NXTM)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

To get a free copy of the research report on NxStage Medical (NXTM), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

...